COPD Management Guidelines

Initial Assessment and Classification

The American Thoracic Society recommends that COPD patients be classified into groups A, B, C, or D based on symptom burden and exacerbation history 1, 3
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifies Group A as low symptoms, low exacerbation risk, Group B as high symptoms, low exacerbation risk, Group C as low symptoms, high exacerbation risk, and Group D as high symptoms, high exacerbation risk 1, 2, 3

The American College of Chest Physicians recommends initial therapy with Short-acting bronchodilator (SABA or SAMA) as needed for symptom relief in Group A patients 1, 2
The European Respiratory Society suggests that for Group B patients, initial therapy should be Long-acting bronchodilator (LABA or LAMA) 1, 3
The American Thoracic Society recommends LABA/LAMA combination therapy as initial treatment for Group D patients, with superior patient-reported outcomes and exacerbation prevention compared to monotherapy 1, 2, 3

The American Lung Association strongly recommends smoking cessation for all current smokers 4
The American Thoracic Society recommends pulmonary rehabilitation for patients with high symptom burden (Groups B, C, and D) 1, 3
The European Respiratory Society suggests that exercise training should combine constant load or interval training with strength training 1

The American College of Chest Physicians recommends short-acting bronchodilators as first-line treatment for exacerbations 6, 7
The Infectious Diseases Society of America recommends systemic corticosteroids (40mg prednisone daily for 5 days) to improve recovery time and lung function 6
The American Thoracic Society recommends non-invasive ventilation as first-line ventilatory support in acute respiratory failure 6

The American Thoracic Society suggests that alpha-1 antitrypsin augmentation therapy may be considered for patients with severe hereditary deficiency and established emphysema 1, 3
The European Respiratory Society recommends against the use of antitussives 3
The American College of Chest Physicians warns that ICS use increases the risk of pneumonia, especially in current smokers, older patients, those with prior exacerbations/pneumonia, low BMI, or severe airflow limitation 8